Stea is board-certified in radiation oncology and practices general radiation oncology with emphasis in lymphomas , pediatric malignancies and brain tumors.  He also has special interest in the application of stereotactic radiosurgery and radiotherapy for the treatment of benign and malignant intracranial diseases.

Dr. Stea has been a pioneer in the treatment of spinal lesions with stereotactic radiosurgery. His laboratory interests are focused on novel radiosensitizing drugs that can be integrated in the treatment of radioresistant cancers. Dr. Stea is the Principal Investigator for “Image Guided Radiation Therapy for Lung Cancer” funded by a grant from the Brown Family Foundation.

Current Research Protocols:

• A Phase II Study to Evaluate the Efficacy and Safety of RSR13 Administered to Patients Receiving Standard Cranial Radiation Therapy for Brain Metastases (RSR13 RT-008)
• A Phase 3 Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without RSR13 in Patients with Brain Metastases (RSR13 RT-009)
• A Phase 3 Randomized, Open-Label Comparative Study of Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (Efaproxiral) in Women with Brain Metastases from Breast Cancer (RSR13 RT-016)
• A Phase I/II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 Administered to Patients receiving a Course of Cisplatin and Radiation Therapy for Locally Advanced Carcinoma of the Cervix (RSR13 RT-012)
• A Phase II Study of Induction Chemotherapy with Paclitaxel and Carboplatin Followed by Radiation Therapy with RSR13 for Locally Advanced Inoperable Non-Small Cell Lung Cancer (RSR13 RT-010)
• A Phase I Open-Label Study of RSR13 (Efaproxiral) and Supplemental Oxygen with Concurrent Paclitaxel, Carboplatin, and Thoracic Radiation Therapy in Patients with Locally Advanced, Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer (RSR13 RT-014)

• Shaw E, Scott C, Suh J, Kadish S, Stea B , Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, and Gerber M. RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 21, 2364-2371, 2003
• Stea B , Falsey R, Kislin K, Patel J. Glanzberg H. Carey S, Ambrad AA, Meuillet EJ, Martinez JD. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EFT receptor tyrosine kinase inhibitor ZD1839 (Iressa). Cancer Letters 202,43-51, 2003
• Choy H, Nabid A, Stea B , Scott C, Roa W, Kleinberg L, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ. Phase II multicenter study of induction chemotherapy followed by concurrent Efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small cell lung cancer. J Clin Oncol 23, 5918-28, 2005
• Suh J, Stea B, Nabid A, Kresl J, Fortin A, Mercier JP, Senzer N, Chang E, Boyd AP, Cagnoni PJ, Shaw E. Results from a phase III study evaluating Efaproxiral as an adjunct to whole brain radiation therapy for the treatment of patients with brain metastases. NEJM (in press)

• Jesse Martinez, PhD and Emmanuelle Meuillet, Ph.D. – Signal Transduction Inhibitors
• Linda Garland, MD – Efaproxiral for Lung Cancer
• Abhay Sanan , MD and Maria Bishop , MD – Brain Tumor Therapy
• Kate Dixon, PhD – Radiation Repair Mechanisms